白云山(00874.HK)拟分拆广州医药到港交所上市及广州医药申请增加不超135亿元授信额度
格隆汇9月10日丨白云山(00874.HK)发布公告,公司第七届董事会第二十六次会议于2019年9月10日召开,审议通过《关于授权公司管理层启动分拆公司子公司到香港联合交易所有限公司上市相关筹备工作的议案》。基于公司战略布局需要,为进一步拓宽境外融资渠道,加速公司国际化战略的实施,公司拟启动分拆子公司广州医药有限公司到香港联合交易所有限公司上市的前期筹备工作。鉴于医药公司分拆上市事项较为复杂,涉及的内外部审批程序较多,为保证医药公司分拆上市工作的顺利进行,同意授权公司管理层先行启动筹备分拆医药公司到香港联合交易所有限公司上市的相关准备工作。
审议通过《关于公司控股子公司广州医药有限公司向银行申请增加综合授信额度的议案》。医药公司作为商业流通企业,在广州GPO中标后,加大了药品储备采购;同时,医药公司业务结构进行了调整,对医院销售的比重有所提高,营运资金需求不断加大。为保证该公司日常经营顺利开展,医药公司及其子公司拟向银行申请增加不超过人民币135亿元的综合授信额度,借款合同签署的有效期截至2020年6月30日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.